New genetic and non-genetic therapies for Duchenne muscular dystrophy are in clinical trials and being approved. Deciding which therapy is right for which patient is evolving. This education addresses dystrophin disruption and restoration, the latest clinical trial results across various treatment modalities, and a case to consider new patient management approaches.